Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

• Fredrik Schjesvold,
• Paul G. Richardson,
• Thierry Facon,
• Adrián Alegre,
• Andrew Spencer,
• Artur Jurczyszyn,
• Kazutaka Sunami,
• Laurent Frenzel,
• Chang-Ki Min,
• Sophie Guillonneau,
• Peggy L. Lin,
• Solenn Le-Guennec,
• Frank Campana,
• Helgi van de Velde,
• Samira Bensfia,
• Sara Bringhen

Affiliations

Fredrik Schjesvold

Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway

Paul G. Richardson

Dana-Farber Cancer Institute, Boston, MA, USA

Thierry Facon

Lille University Hospital, Lille, France

Adrián Alegre

Hospital Universitario La Princesa and Hospital Quironsalud, Madrid, Spain

Andrew Spencer

Department of Clinical Hematology, Alfred Health-Monash University, Melbourne, Australia

Artur Jurczyszyn

Department of Hematology, Jagiellonian University Medical College, Krakow, Poland

Kazutaka Sunami

Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan

Laurent Frenzel

Hôpital Necker-Enfants Malades, Paris, France

Chang-Ki Min

Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of South Korea

Sophie Guillonneau

Sanofi CMO, Chilly-Mazarin, France

Peggy L. Lin

Sanofi Global Oncology, Cambridge, MA, USA

Solenn Le-Guennec

Sanofi RD, Vitry-sur-Seine, France

Frank Campana

Sanofi RD, Cambridge, MA, USA

Helgi van de Velde

Sanofi RD, Cambridge, MA, USA

Samira Bensfia

Sanofi Global Oncology, Cambridge, MA, USA

Sara Bringhen

Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy